Comorbidity: non-alcoholic fatty liver disease and psoriasis
O. B. Nemchaninova,
E. Yu. Sklyanova,
S. G. Lykova,
E. N. Makhnovets,
O. N. Pozdnyakova,
T. B. Reshetnikova,
A. A. Khryanin https://doi.org/10.31146/1682-8658-ecg-194-10-55-60
Abstract
Non-alcoholic fatty liver disease (NAFLD), being a marker of significant changes in the hepatobiliary system against the background of metabolic syndrome and other endocrine pathologies, has a significant impact on the course of psoriatic disease. The presence of common mechanisms in the pathogenesis of these diseases suggests a very close relationship between them. This requires a multidisciplinary approach to studying the mechanisms of the pathogenesis of psoriasis and NAFLD, which will improve the methods of diagnosis and treatment of both diseases.
About the Authors
O. B. Nemchaninova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Olga В. Nemchaninova - doctor of medical sciences, professor, Head of the department of a dermatovenereology and cosmetology.
52, Krasny Prospect, Novosibirsk, 630091.
E. Yu. Sklyanova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Elena Yu. Sklyanova - candidate of medical sciences, associate professor of the department of dermatovenereology and cosmetology.
52, Krasny Prospect, Novosibirsk, 630091.
S. G. Lykova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Sof'ya G. Lykova - doctor of medical sciences, professor of department of dermatovenereology and cosmetology.
52, Krasny Prospect, Novosibirsk, 630091.
E. N. Makhnovets
Novosibirsk State Medical University
Russian Federation
Russian Federation
Evgeny N. Makhnovets - candidate of medical sciences, associate professor of the department of dermatovenereology and cosmetology.
52, Krasny Prospect, Novosibirsk, 630091.
O. N. Pozdnyakova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Olga N. Pozdnyakova - doctor of medical sciences, professor of department of dermatovenereology and cosmetology.
52, Krasny Prospect, Novosibirsk, 630091.
T. B. Reshetnikova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Tatiyana B. Reshetnikova - doctor of medical sciences, professor of the department of a dermatovenereology and cosmetology.
52, Krasny Prospect, Novosibirsk, 630091.
A. A. Khryanin
Novosibirsk State Medical University
Russian Federation
Russian Federation
Aleksey A. Khryanin - doctor of medical sciences, professor of the department of a dermatovenereology and cosmetology.
52, Krasny Prospect, Novosibirsk, 630091.
References
1. Peresada E.I., Vavilova T. V., Basharin V. A., Kutsenko V. P. Functional condition of liver is a factor of safety and efficiency of everolimus therapy. Experimental and Clinical Gastroenterology. 2019;(8):53-60. (In Russ.) doi: 10.31146/1682-8658-ecg-168-8-53-60.
2. Drapkina O. M., Ivashkin V. T. Epidemiological peculiarities of non-alcoholic fatty liver disease in Russia (results of open multi-center prospective survey DIREGL 01903). Ros. Jurn. gastroenterol., hepatol., coloproctol. 2014; 24 (4): 32-8. (In Russ.)
3. Lazebnik L. B., Radchenko V. G., Golovanova E. V. et al. Non-alcoholic Liver Fat Disease: Clinic, Diagnosis, Treatment. Recommendations for Physicians. Therapy. 2016;2 (6):6-18. (In Russ.)
4. Shipovskaya A.A., Dudanova O. P., Kurbatova I. V., Larina N. A. Inflammation and insulin resistance in the progression of early forms of non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2019;(8): 23-28. (In Russ.) doi: 10.31146/1682-8658-ecg-168-8-23-28.
5. Benedict M., Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J. Hepatol. 2017, Vol. 16, pp. 715-732. doi: 10.4254/wjh.v9.i16.715.
6. Akhmedov V. A., Melikov T. I. Non-alcoholic fatty liver disease and psoriasis: random combination or regular relationship? Medical alphabet. 2019;4(38):5-8. (In Russ.). doi: 10.33667/2078-5631-2019-4-38(413) - 5-8.
7. Federal State Statistics Service. Russian Federation Population Base by gender and age on 1 January 2010 (Statistical bulletin). Moscow, 2010. Available at: https://rosstat.gov.ru/compendium/document/13284. (In Russ.)
8. Russian Federation Population Base by gender and age on 1 January 2019 (Statistical bulletin). Moscow, 2019. Available at: https://rosstat.gov.ru/compendium/document/13284. (In Russ.)
9. Kubanov А.А., Bogdanova E. V. Epidemiology of psoriasis among the elderly population and volume of specialized medical care provided to patients with psoriasis in the Russian Federation in 2010-2019. Vestnik Dermatologii i Venerologii. 2020;96(5):07-18. (In Russ.) doi: 10.25208/vdv1171-2020-96-5-07-18.
10. Masallar, D., Moemen, D., State, A. F. Gut bacterial microbiota in psoriasis: A case control study. Afr. J. Microbiol. Res. 2016;10:1337-1343. doi: 10.5897/AJMR2016.8046.
11. Denisova E., Dvyanyankova E., Denieva M., et al. Justification of the use of hepatoprotectors in psoriasis. Doctor. 2018; (9): 85-88. (In Russ.) doi: 10.29296/25877305-2018-09-20.
12. Korsakova Yu.L., Korotaeva T. V. Liver damage in psoriasis and psoriatic arthritis: a literature review. Rheumatology Science and Practice. 2017;55(4):429-435. (In Russ.) doi: 10.14412/1995-4484-2017-429-435.
13. Hamaganova I.V., Almazova A. A., Lebedeva G. A., Ermachenko A. V. Problems of psoriasis epidemiology. Clinical dermatology and venereology. 2015, no. 1, pp.12-16. (in Russ.)
14. Parisi R., Symmons D. P.M., Griffiths C. E.M., Ashcroft D.M, The Identification and Management of Psoriasis and Associated Comorbidity project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology. 2013; 133:377-385. doi: 10.1038/jid.2012.339.
15. Butov Y.S., Mordovtseva V. V., Vasenova V. Y., Shmakova A. S. Psoriasis. In.: Dermatovenerology. National Manual. Short Edition. Moscow. 2013. (in Russ.)
16. Enamandram M., Kimball A. B. Psoriasis epidemiology: the interplay of genes and the environment. J Invest Dermatol. 2013; 133(2): 287-289. doi: 10.1038/jid.2012.434.
17. Onumah N., Kircik L. H. Psoriasis and its comorbidities. J Drugs Dermatol. 2012; (11):5-10. doi: 10.2147/CCID.S44843.
18. Farley E., Menter A. Psoriasis: comorbidities and associations. Ital. Dermatol. Venereol. 2011;146:9-15.
19. Davidovici B.B, Sattar N., Prinz J.C, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J. Invest. Dermatol. 2010;130:1785-96. doi: 10.1038/jid.2010.103.
20. Yarilin A. A. Cytokine system and principles of its normal and pathological functioning. Immunology. 1997;(5):7-14. (In Russ.)
21. Ovsyannikov V. G. General pathology (pathological physiology). Part I (general pathophysiology), edition 4: Rostov-n.d. FGOB V RostGMU Ministry of Health Publ. 2017. pp. 224-248. (In Russ.)
22. Rosumbaeva L. P., Kozlova I. V., Bykova A. P., et al. Pathology of the hepatobiliary system and psoriasis: interrelationships and interactions. Contemporary problems of science and education. 2014;(4): 21-27. (In Russ.)
23. Dashuk A. M., Chipizhenko V. A., Chernikova L. I., et al. Psoriasis and pathology of the hepatobiliary system. Topical issues of dermatology, venereology and HIV/AIDS infection: a collection of scientific works dedicated to the 90th anniversary of the birth of Professor B. A. Zadorovsky. 2013. pp. 98-103. (In Russ.)
24. Koppe S. W. Obesity and the liver: nonalcoholic fatty liver disease. Per RES. 2014;(164): 312-322. doi: 10.1016/j.trsl.2014.06.008.
25. Kalb R., Strober B., Weinstein G. et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J. Am. Acad dermatol. 2009; 60 (5): 824-37. doi: 10.1016/j.jaad.2008.11.906.
26. Lindsay K., Fraser A., Layton A. et al. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford). 2009; 48 (5): 569-72. doi: 10.1093/rheumatology/kep023
27. Smirnova S. V., Barilo A. A., Smolnikova M. V. Hepatobiliary System Diseases as the Predictors of Psoriasis Progression. Annals of the Russian Academy of Medical Sciences. 2016;71(2):102-108. (In Russ.) doi: 10.15690/vramn636.
28. Bakulev A. L., Kravchenya S. S. Use of hepatoprotectors in psoriasis: Comparative clinical-laboratory and ultramodern effectiveness evaluation. Herald of dermatology and venereology. 2010;(1): 112-117. (In Russ.) doi: 10.25208/vdv880.
29. Voort E.A., Koehler E. M., Dowlatshahi E. A., et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population based study. J. Am. Acad. Dermatol. 2014;70(3):517-524. doi: 10.1016/j.jaad.2013.10.044.
30. Livzan M.A., Gaus O. V., Nikolaev N. A., Krolevetz T. S. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;-1(10):57-65. (In Russ.). doi: 10.31146/1682-8658-ecg-170-10-57-65.
31. Pietrzak D., Pietrzak A., Krasowska D., et al. Digestive system in psoriasis: an update. Arch. Dermatol. Res. 2017; 309 (9): 679-93. doi: 10.1007/s00403-017-1775-7.
32. Ganzetti G., Campanati A., Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J. Hepatol, 2015; (7): 315-326. doi: 10.4254/wjh.v7.i3.315.
33. Van der Voort E. A., Koehler E. M., Dowlatshahi E. A., et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am. Acad. Dermatol. 2014; (70): 517-524. doi: 10.1016/j.jaad.2013.10.044.
34. Iblyaminova A. A. Psoriasis and biliary pathology: features of current and therapy. Cand. diss. Med. Scien. Yekaterinburg. 2011, 22p. (In Russ.)
35. Rosumbaeva L. P., Koslova I. V., Bykova A. P. Comorbidity of liver, biliary tract and psoriasis diseases. Experimental and Clinical Gastroenterology. 2015;2(14): 24-28. (In Russ.)
36. Korsunskaya I. M., Piruzyan A. L., Sakania L. R., et al. Effective pharmacotherapy. Dermatovenereology and dermatocomestology. 2016;(1-2): 2-7. (In Russ.)
37. Lonardo A., Ballestri S., Marchesini G. et al. Nonalcoholic fatty liver disease: Aprecursor of the metabolic syndrome. Dig. Liver Dis. 2015;(47): 181-190. doi: 10.1016/j.dld.2014.09.020.
38. Gisondi P., Barba E., Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 2015; (30): 282-287. doi: 10.1111/jdv.13456.
39. Abedini R., Salehi M., Lajevardi V., Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin. Exp. Dermatol. 2015; (40): 722-727. doi: 10.1111/ced.12672.
40. Kulkarni N. M., Jaji M. S., Shetty P., et al. A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation. Pharm. Biol. 2015; (53): 1110-1117. doi: 10.3109/13880209.2014.960944.
Review
For citations:
Nemchaninova O.B., Sklyanova E.Yu., Lykova S.G., Makhnovets E.N., Pozdnyakova O.N., Reshetnikova T.B., Khryanin A.A. Comorbidity: non-alcoholic fatty liver disease and psoriasis. Experimental and Clinical Gastroenterology. 2021;(10):55-60. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-194-10-55-60
Views:
449
Email this article 